Kyle Gowen

Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

Transcriptomic definition of molecular subgroups of small round cell sarcomas

Genome-wide CRISPR/Cas9 Screen Identifies Host Factors Essential for Influenza Virus Replication

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

The biology and management of non-small cell lung cancer

Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer

Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond

Inflammation and tumor progression: signaling pathways and targeted intervention

Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease

Regulation and Function of the PD-L1 Checkpoint

The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives

Applications of machine learning in drug discovery and development

Immune checkpoint inhibitors: recent progress and potential biomarkers

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition

A guide to cancer immunotherapy: from T cell basic science to clinical practice

Tumour heterogeneity and resistance to cancer therapies

Regression of Chemotherapy-Resistant Polymerase ϵ (POLE) Ultra-Mutated and MSH6 Hyper-Mutated Endometrial Tumors with Nivolumab

Bringing the Next Generation of Immuno-Oncology Biomarkers to the Clinic

Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy

Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition

Inactivation of Capicua drives cancer metastasis

TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling

Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA).

Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP).

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies.

Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer.